Maghsoud Dariani has over 30 years of diverse and progressive management experience in the development and commercialization of products in the pharmaceutical industry. Mr. Dariani has a successful record of business management, strategic planning, acquisition and divestiture, project management, production management, R&D management, economic evaluations, competitor analyses, and development and administration of multi-million dollar budgets. Mr. Dariani is also an entrepreneurial business leader with a sound grasp of successful business strategies, with an excellent foundation in science and engineering, and a strong background in product development and commercialization. Concurrent to leading science and technology efforts at Myos Rens, he is also President and CEO of Semorex Inc. – a privately held company focused on the discovery and development of novel therapeutics for cancer. Prior to joining MYOS and Semorex, Mr. Dariani was President of Focus Pharmaceuticals, Inc., where he managed the development and approval of drug products, achieving one FDA approval and bringing another to the clinical evaluation stage, then successfully negotiated the sale of the company in February 2003. Prior to Focus, Mr. Dariani was Vice President of the chiral pharmaceutical business unit at Celgene Corporation. During his twelve years at Celgene, Mr. Dariani developed and implemented Celgene’s manufacturing strategy, managed and successfully sold Celgene’s chiral intermediates business unit, and formulated a strategic plan for leveraging Celgene’s expertise in chiral technologies towards the development of chirally pure drug products. Mr. Dariani was responsible for the successful development and FDA approval of the chirally pure versions of Ritalin, which are currently marketed by Novartis under the Focalin and Focalin XR trade names. Prior to Celgene, Mr. Dariani held progressively more responsible engineering and development positions at Celanese Corporation. Mr. Dariani holds a BS degree from The City College of NY and an MS degree from University of Massachusetts in Chemical Engineering.